OPTN - OptiNose, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.84
+0.20 (+2.31%)
As of 11:12AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close8.64
Open8.74
Bid8.81 x 800
Ask8.84 x 800
Day's Range8.60 - 8.87
52 Week Range4.44 - 11.66
Volume57,467
Avg. Volume280,112
Market Cap367.582M
Beta (3Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • How health startup Optinose engineered a 300%+ spike in growth
    Yahoo Finance

    How health startup Optinose engineered a 300%+ spike in growth

    Optinose is a $400 million market cap company that's hoping to be a leader in the ears, nose and throat (ENT) space.

  • Hedge Funds Have Never Been More Bullish On OptiNose, Inc. (OPTN)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On OptiNose, Inc. (OPTN)

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Earnings Preview: OptiNose (OPTN) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: OptiNose (OPTN) Q3 Earnings Expected to Decline

    OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Globenewswire Test

    Optinose Appoints Michael Richardson to New Position of Vice President, Business Development

    YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) --  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported the creation of a new role of Vice President, Business Development and appointment of Michael Richardson into the new position. In this role, Michael will be responsible for identifying, evaluating, and executing on business development opportunities that support the overall corporate strategy. "While our team continues to focus the bulk of our resources on the commercial launch of XHANCE® and on achieving our near-term objectives, we feel it is also important to start dedicated efforts toward evaluation of opportunities that leverage our capabilities, the capabilities of other organizations, or create new options for supporting longer-term growth,” said Chief Executive Officer Peter Miller. “Michael has a successful track-record as a business development leader in the pharmaceutical industry and we are confident his efforts can help us advance our mission to further accelerate the growth of XHANCE and to build a leading ENT and allergy company.”Michael joins Optinose from Princeton Biopharma where he led their commercial activities. Prior to Princeton Biopharma, Michael had roles of increasing responsibility at Grunenthal, Cephalon, and Johnson & Johnson.  Michael earned his MBA at Duke University and his BA at West Virginia University.About Optinose Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements regarding XHANCE growth, the Company's future operations, financial performance, financial position, prospects, objectives and other future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: physician and patient acceptance of XHANCE; the Company’s ability to maintain adequate third-party reimbursement for XHANCE (market access); market opportunities for XHANCE may be smaller than expected; the Company’s ability to grow XHANCE prescriptions; and the risks, uncertainties and other factors discussed under the caption "Item 1A. Risk Factors" and elsewhere in the Company’s most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission - which are available at www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statements made in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise.Optinose Investor Contact Jonathan Neely jonathan.neely@optinose.com 267.521.0531

  • Is OptiNose (NASDAQ:OPTN) Using Debt In A Risky Way?
    Simply Wall St.

    Is OptiNose (NASDAQ:OPTN) Using Debt In A Risky Way?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

  • Benzinga

    OptiNose's Q2 Results Reflect Strong Underlying Trends, RBC Says

    OptiNose Inc’s (NASDAQ: OPTN ) XHANCE nasal spray continued to exhibit encouraging trends in the second quarter, suggesting that the company's launch is progressing on track, according to RBC Capital Markets. ...

  • OptiNose, Inc. (OPTN) Q2 2019 Earnings Call Transcript
    Motley Fool

    OptiNose, Inc. (OPTN) Q2 2019 Earnings Call Transcript

    OPTN earnings call for the period ending June 30, 2019.

  • OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
    Zacks

    OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates

    OptiNose (OPTN) delivered earnings and revenue surprises of 12.00% and -13.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Analysts Estimate OptiNose (OPTN) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate OptiNose (OPTN) to Report a Decline in Earnings: What to Look Out for

    OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Those Who Purchased OptiNose (NASDAQ:OPTN) Shares A Year Ago Have A 73% Loss To Show For It
    Simply Wall St.

    Those Who Purchased OptiNose (NASDAQ:OPTN) Shares A Year Ago Have A 73% Loss To Show For It

    OptiNose, Inc. (NASDAQ:OPTN) shareholders should be happy to see the share price up 14% in the last month. But that...

  • InvestorPlace

    You Can Get Buy Signals From Short Selling

    You may be surprised to hear this, but a large amount of short interest in a stock could actually be a buy signal.What is short selling a stock? It's selling a stock that you don't own with the intention of buying it back at a lower price in the future, usually using options. And short interest is the number of shares that are sold short that haven't been bought back yet. It is usually expressed as a ratio of shares that are short to the total number of outstanding shares.The short interest can also be expressed as "Days to Cover." This is the number of short shares divided by the average daily trading volume. In other words, it is the number of days that it would take for all the short shares to be bought back.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI should note, this number should be considered understated, because it assumes purchasing 100% of the volume. This would be impossible in normal markets. It would be more realistic to assume that short sellers could only buy about 10%-15% of the average daily volume with adversely affecting the price. * 7 Safe Stocks to Buy for Anxious Investors You should pay attention to this because really high short-interest could be a bullish signal. This is because these shares need to be bought back. These short-sellers will all eventually become buyers! Trupanion (TRUP)Trupanion (NASDAQ:TRUP) provides medical insurance for cats and dogs. It has a subscription business and also offers insurance to companies that can provide it as a benefit to their employees.There are about 11.2 million shares currently short. This is 38% of the outstanding float. The average daily volume recently is about 145,000. That means the days to cover would be about 77. And remember, that assumes buying 100% of the volume.It would be more realistic to assume that one could only trade about 10% of the volume without adversely affecting the price. That means it could take years for the shorts to cover all of their positions!Wall Street seems to disagree with the shorts. Six firms follow it and the all have buy ratings on it. The average price target is $40. Accelerate Diagnostics (AXDX)Accelerate Diagnostics (NASDAQ:AXDX) engages in developing and selling instruments that are used to fight infectious pathogens.There are 14.1 million shares currently short in this company. That is 52% of the float. That means that there are guaranteed buyers for about half of the company's stock! Assuming that they buy 10% of the average daily volume, it would take about two years to cover it. * 7 Stocks to Buy for Over 20% Upside Potential All four of the analysts who cover this have a buy rating on it according to Yahoo Finance. OptiNose (OPTN)OptiNose (NASDAQ:OPTN) develops and sells products that are for the treatment of ear, nose, throat and allergy illnesses.The short-interest is 7.9 million, or about 49% of the float. Over the past year, the price of the stock has fallen from $30 to current levels around $9.Wall Street doesn't feel as bad about this company's prospects as the short sellers do. It likes this stock. All four analysts that follow it have it rated as a buy and the average target price is $25. That is about three times higher then where it is currently trading. Energy Recovery (ERII)Energy Recovery (NASDAQ:ERII) develops and sells products that are for industrial fluid flow application. Their customers include oil and gas companies.5.5 million shares are currently short. That is about 14% of the float. It isn't as much as the other companies, but it is still pretty high. It only trades about 112,000 on a typical day, so that would give a days to cover number of about 50. Using our estimate of being able to only acquire about 10%-15% of the volume that trades with adversely affecting the price, it would take over a year to cover. * 7 High-Yield REITs to Buy (Even When the Market Tanks) There are six buys on this company. The average target price is about $16, which is about 60% above current prices. Seres Therapeutics (MCRB)Seres Therapeutics (NASDAQ:MCRB) creates medicines "using live bacteria to treat diseases that result from functional deficiencies in the microbiome."The share price fell dramatically over the past month. The current short interest is 5.3 million of the float. That is about 25%. With an average daily volume of about 111,000, the days to cover is 48.This company is followed by nine Wall Street firms. Seven have it rated as a buy and the other two have it as a hold. The average target price is $11 and it is currently trading below $5. Theravance Biopharma (TBPH)Theravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company. It focuses and the research, development and commercialization of small molecule medicines.The short-interest ratio here is "only" 15%, or 6.3 million shares. The stock only trades about 154,000 shares on a typical day, so that is 41 days to cover.Remember, it is safe to assume that they can buy about 10% of the volume without adversely affecting the price. * 6 Chinese Stocks That Could Pop On a Trade Deal Seven firms follow this company. Four of them have it rated a buy and three have it as a sell. The average target price is just over $38 per share.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post You Can Get Buy Signals From Short Selling appeared first on InvestorPlace.

  • OptiNose, Inc. (OPTN) Q1 2019 Earnings Call Transcript
    Motley Fool

    OptiNose, Inc. (OPTN) Q1 2019 Earnings Call Transcript

    OPTN earnings call for the period ending March 31, 2019.

  • OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

    OptiNose (OPTN) delivered earnings and revenue surprises of 1.41% and 2.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    OptiNose: 1Q Earnings Snapshot

    On a per-share basis, the Yardley, Pennsylvania-based company said it had a loss of 70 cents. The specialty pharmaceutical company posted revenue of $4.5 million in the period. OptiNose shares have climbed ...

  • OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Have Insiders Been Buying OptiNose, Inc. (NASDAQ:OPTN) Shares?
    Simply Wall St.

    Have Insiders Been Buying OptiNose, Inc. (NASDAQ:OPTN) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So shareholders might...

  • Benzinga

    OptiNose Analysts Projects Prescription Growth In 2019, Beyond

    OptiNose In c (NASDAQ: OPTN ) has introduced a new and simplified co-pay assistance program that's led to good script performance, according to Cantor Fitzgerald. The ear, nose and throat drugmaker expects ...

  • OptiNose, Inc. (OPTN) Q4 2018 Earnings Conference Call Transcript
    Motley Fool

    OptiNose, Inc. (OPTN) Q4 2018 Earnings Conference Call Transcript

    OPTN earnings call for the period ending December 31, 2018.

  • OptiNose, Inc. (NASDAQ:OPTN): Time For A Financial Health Check
    Simply Wall St.

    OptiNose, Inc. (NASDAQ:OPTN): Time For A Financial Health Check

    Investors are always looking for growth in small-cap stocks like OptiNose, Inc. (NASDAQ:OPTN), with a market cap of US$248m. However, an important fact which most ignore is: how financially healthy Read More...

  • Benzinga

    The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

    Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...